Fresenius Medical Care AG & Co. KGaA Sponsored ADR Aktie News

Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hofsäß will retire by year end BAD HOMBURG, Germany , Oct. 1, 2025 /PRNewswire/ -- The Supervisory Board of Fresenius Medical Care (FME), the world's leading provider of products and services for indi...

Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set during the merger of Cricket Health, IWH, and Fresenius Health Partners when it was completed in August 2022 Tommy P. O'Connor appointed CEO of Interwell Health and Operating Segment leader of Value...

Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, announced the launch of the first tranche of its initial EUR 1 billion share buyback, which i...

Fresenius Medical Care AG (NYSE:FMS ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants s - Corporate Participant o - Corporate Participant P - Corporate Participant Dominik Heger - Executive VP and Head of Investor Relations, Strategic Development & Communications Helen Giza - Chair of Management Board & CEO Martin Fischer - CFO & Member of the Management Board Conference Ca...

Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed to earnings Operating income2 grew by 13% at constant currency, further driving margin expansion Stable reported operating income and 20% increase in reported net income3 Operating cash flow improve...

Fresenius Medical Care (FMS) is rated a buy, with shares up 32.95% YoY and strong Q1 2025 results, showing 60% (YoY) net income growth. My valuation using a forward P/S ratio suggests FMS is undervalued by over 130%, with a projected share price of $62.06 by 2026. Compared to peers, FMS offers the highest potential upside and a superior 3.07% dividend yield, making it an attractive value play.

Explore the latest report on the global outpatient clinics market, analyzing trends, revenue, and forecasts from 2023 to 2029. This comprehensive study covers services, specialty, regional insights, and ESG impacts, featuring profiles of key players like Johns Hopkins and Mayo Clinic. Discover market dynamics and competitive landscape strategies. Explore the latest report on the global outpatie...

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany , July 3, 2025 /PRNewswire...